In recent years we have seen a revolution in the treatment of metastatic melanoma, with the introduction of both immunotherapy and targeted agents, but to date, only a limited number of studies have examined how these drugs are used in clinical practice.
The SYSF team was recently in San Francisco for the Society for Melanoma Research (SMR) 2015 Congress and learned that a new study has looked at the current “real-world treatment patterns of therapies” in patients with metastatic melanoma in the United States. The data was presented during the poster session at the Society for Melanoma Research 2015 Congress in San Francisco.
More information on the study can be found on Medscape.com
